parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in oligodendrocytes (27 nCPM)	1.00
chemistry Open Targets	reachable by antibody	0.36
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 12802

CTDNEP1 in dopamine neurons, braak-0.23 (p 0.555) → -0.68 (p 0.043)receipt 12810
CTDNEP1 in oligodendrocytes, braak-0.09 (p 0.820) → +0.16 (p 0.689)receipt 12809

receipt 12810: CTDNEP1 in dopamine neurons, braak

power: full sample -0.41 (p 0.093, n 18), 95% CI -0.73 to +0.07. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.47 (p 0.047, n 18). holds up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.44 (p 0.069, n 18). could be the mix.
skeptic: leave-one-out range -0.55 to -0.33, sign flips 0; without severely affected donors -0.41 (p 0.093, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CTDNEP1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 12809: CTDNEP1 in oligodendrocytes, braak

power: full sample +0.01 (p 0.969, n 18), 95% CI -0.46 to +0.47. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.04 (p 0.861, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.02 (p 0.935, n 18). could be the mix.
skeptic: leave-one-out range -0.13 to +0.12, sign flips 6; without severely affected donors +0.01 (p 0.969, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CTDNEP1 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts